Sec Form 3 Filing - Loschinskey Dave @ Diplomat Pharmacy, Inc. - 2019-05-02

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Loschinskey Dave 2. Issuer Name and Ticker or Trading Symbol Diplomat Pharmacy, Inc. [ DPLO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O DIPLOMAT PHARMACY, INC., 4100 SOUTH SAGINAW ST. 3. Date of Earliest Transaction (MM/DD/YY) 05/02/2019 (Street) FLINT, MI48507 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 100,822 ( 1 ) D Common Stock 994 I By Spouse ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option to Acquire Common Stock $ 20.87 ( 3 ) 11/06/2027 Common Stock 100,000 D Employee Stock Option to Acquire Common Stock $ 20.52 ( 4 ) 03/27/2028 Common Stock 9,508 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Loschinskey Dave C/O DIPLOMAT PHARMACY, INC. 4100 SOUTH SAGINAW ST. FLINT, MI48507 Chief Operating Officer Signatures /s/ Christina Flint, by Power of Attorney 05/13/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 1,778 restricted stock units granted in connection with the Issuer's equity incentive plan, one half of which will vest on March 27, 2020 and one half of which will vest on March 27, 2021. ( 2 )Shares held directly by the Reporting Person's spouse. ( 3 )The options were granted on November 6, 2017, in connection with the Reporting Person joining the Issuer, under the Issuer's equity incentive plan. One-fourth of the options vested on November 6, 2018 and the remaining three-fourths will vest on each of the second, third and fourth anniversary of the grant date. ( 4 )The options were granted on March 27, 2018 in connection with the Issuer's equity incentive plan. One-third of the options vested on March 27, 2019 and the remaining two-thirds will vest on each of the second and third anniversary of the grant date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.